NASDAQ: BLRX
Biolinerx Ltd Stock

$0.96-0.10 (-9.43%)
Updated Nov 20, 2026
BLRX Price
$0.96
Fair Value Price
N/A
Market Cap
$5.05M
52 Week Low
$0.78
52 Week High
$3.95
P/E
N/A
P/B
0.37x
P/S
9.96x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.39M
Earnings
-$9.29M
Gross Margin
80%
Operating Margin
-592.46%
Profit Margin
-667.3%
Debt to Equity
1.22
Operating Cash Flow
-$11M
Beta
0.83
Next Earnings
Nov 23, 2026
Ex-Dividend
N/A
Next Dividend
N/A

BLRX Overview

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine BLRX's potential to beat the market

Zen Rating Component Grades

N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
BLRX
Ranked
Unranked of 447

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important BLRX news, forecast changes, insider trades & much more!

BLRX News

Overview

Due Diligence Score

–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BLRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BLRX is good value based on its book value relative to its share price (0.37x), compared to the US Biotechnology industry average (4.78x)
P/B vs Industry Valuation
BLRX's cash burn is expected to be positive in the next year ($1.38M), after accounting for decreasing cash burn (87.23%)
Interest Coverage Financials
BLRX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
There are 30 more BLRX due diligence checks available for Premium users.

Valuation

BLRX fair value

Fair Value of BLRX stock based on Discounted Cash Flow (DCF)

Price
$0.96
Fair Value
-$2.45
Undervalued by
139.17%

BLRX price to earnings (PE)

For valuing profitable companies with steady earnings

Company
0x
Industry
16.91x
Market
39.45x

BLRX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
0.37x
Industry
4.78x
BLRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

BLRX's financial health

Profit margin

Revenue
$294.0k
Net Income
-$4.3M
Profit Margin
-1,475.9%
BLRX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
BLRX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$33.5M
Liabilities
$16.9M
Debt to equity
1.22
BLRX's short-term assets ($16.35M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BLRX's short-term assets ($16.35M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BLRX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
BLRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$3.2M
Investing
$6.3M
Financing
-$1.1M
BLRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

BLRX vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
BLRX–$5.05M-9.06%N/A0.37x
ICUD$4.97M-10.95%-0.35x10.60x
PPBT–$4.97M-0.33%N/A0.44x
SNGX–$5.14M-8.33%-0.76x0.82x
CNSP–$5.25M-9.07%-0.20x0.33x

Biolinerx Stock FAQ

What is Biolinerx's quote symbol?

(NASDAQ: BLRX) Biolinerx trades on the NASDAQ under the ticker symbol BLRX. Biolinerx stock quotes can also be displayed as NASDAQ: BLRX.

If you're new to stock investing, here's how to buy Biolinerx stock.

What is the 52 week high and low for Biolinerx (NASDAQ: BLRX)?

(NASDAQ: BLRX) Biolinerx's 52-week high was $3.95, and its 52-week low was $0.78. It is currently -75.59% from its 52-week high and 23.59% from its 52-week low.

How much is Biolinerx stock worth today?

(NASDAQ: BLRX) Biolinerx currently has 2,620,977,000 outstanding shares. With Biolinerx stock trading at $0.96 per share, the total value of Biolinerx stock (market capitalization) is $5.05M.

Biolinerx stock was originally listed at a price of $3,018.00 in Jul 27, 2011. If you had invested in Biolinerx stock at $3,018.00, your return over the last 15 years would have been -99.97%, for an annualized return of -41.53% (not including any dividends or dividend reinvestments).

How much is Biolinerx's stock price per share?

(NASDAQ: BLRX) Biolinerx stock price per share is $0.96 today (as of Nov 20, 2026).

What is Biolinerx's Market Cap?

(NASDAQ: BLRX) Biolinerx's market cap is $5.05M, as of Nov 21, 2026.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Biolinerx's market cap is calculated by multiplying BLRX's current stock price of $0.96 by BLRX's total outstanding shares of 2,620,977,000.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.